- Home
- HQI vs PLX Comparison
HQI vs PLX Comparison
Compare HQI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- PLX
- Stock Information
- Founded
- HQI 2002
- PLX 1993
- Country
- HQI United States
- PLX United States
- Employees
- HQI N/A
- PLX N/A
- Industry
- HQI Professional Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQI Consumer Discretionary
- PLX Health Care
- Exchange
- HQI Nasdaq
- PLX Nasdaq
- Market Cap
- HQI 143.3M
- PLX 122.6M
- IPO Year
- HQI N/A
- PLX 1998
- Fundamental
- Price
- HQI $9.82
- PLX $1.37
- Analyst Decision
- HQI Strong Buy
- PLX Strong Buy
- Analyst Count
- HQI 2
- PLX 1
- Target Price
- HQI $16.00
- PLX $15.00
- AVG Volume (30 Days)
- HQI 14.9K
- PLX 1.3M
- Earning Date
- HQI 08-07-2025
- PLX 08-13-2025
- Dividend Yield
- HQI 2.49%
- PLX N/A
- EPS Growth
- HQI N/A
- PLX N/A
- EPS
- HQI 0.24
- PLX 0.05
- Revenue
- HQI $33,651,000.00
- PLX $59,764,000.00
- Revenue This Year
- HQI N/A
- PLX $65.02
- Revenue Next Year
- HQI $4.99
- PLX $57.34
- P/E Ratio
- HQI $39.80
- PLX $28.34
- Revenue Growth
- HQI N/A
- PLX 0.18
- 52 Week Low
- HQI $9.04
- PLX $0.82
- 52 Week High
- HQI $15.75
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- HQI 48.58
- PLX 41.78
- Support Level
- HQI $10.20
- PLX $1.43
- Resistance Level
- HQI $10.41
- PLX $1.54
- Average True Range (ATR)
- HQI 0.19
- PLX 0.09
- MACD
- HQI -0.01
- PLX 0.01
- Stochastic Oscillator
- HQI 43.25
- PLX 5.77
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.